Objective Compare the efficacy of entacapone and piribedil sustained-release tablets in the treatment of dyskinesia in patients with Parkinson's disease. Methods 35 patients were selected, and 18 cases were randomly divided into treatment group(add entacapone), 17 cases into the control group(add piribedil sustained-release tablets). The control group was given levodopa tablets plus piribedil sustained-release tablets; the treatment group received levodopa tablets and entacapone. Clinical efficacy was observed in the two groups after 12 weeks of treatment. Result The treatment group was significantly better than the control group, a statistically significant difference. Conclusion Entacapone combined with levodopa in the treatment of dyskinesia in patients with Parkinson's disease is more effective than the control group, can significantly improve the quality of life of patients with Parkinson's disease.
NETL
NSTL
万方数据
维普
